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Urinary Nitrate Might Be an Early Biomarker for Pediatric
Acute Kidney Injury in the Emergency Department
ASAD I. MIAN, YUE DU, HARSHA K. GARG, A. CHANTAL CAVINESS, STUART L. GOLDSTEIN, AND NATHAN S. BRYAN
Department of Pediatrics [A.I.M., Y.D., A.C.C.], Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas 77030;
Department of Pediatrics [S.L.G.], Cincinnati Children’s Hospital, Cincinnati Ohio 45229; Texas Therapeutics Institute [H.K.G., N.S.B.],
University of Texas Houston Health Science Center, Houston, Texas 77030
ABSTRACT: NO is involved in normal kidney function and per-
turbed in acute kidney injury (AKI). We hypothesized that urinary
concentration of NO metabolites, nitrite, and nitrate would be lower
in children with early AKI presenting to the emergency department
(ED), when serum creatinine (SCr) was uninformative. Patients up to
19 y were recruited if they had a urinalysis and SCr obtained for
routine care. Primary outcome, AKI, was defined by pediatric Risk,
Injury, Failure, Loss of function, End-stage renal disease (pRIFLE)
criteria. Urinary nitrite and nitrate were determined by HPLC. A total
of 252 patients were enrolled, the majority (93%) of whom were
without AKI. Although 18 (7%) had AKI by pRIFLE, 50% may not
have had it identified by the SCr value alone at the time of visit.
Median urinary nitrate was lower for injury versus risk (p  0.03);
this difference remained significant when the injury group was com-
pared against the combined risk and no AKI groups (p  0.01).
Urinary nitrite was not significantly different between groups.
Thus, low urinary nitrate is associated with AKI in the pediatric
ED even when SCr is normal. Predictive potential of this putative
urinary biomarker for AKI needs further evaluation in sicker
patients. (Pediatr Res 70: 203–207, 2011)
Acute kidney injury (AKI), previously referred to as acuterenal failure (ARF), is a common complication among
ambulatory and hospitalized patients (1,2). The incidence of
AKI varies from 5% in hospitalized patients to 30–82% of
patients in intensive care units (ICUs) (3,4). Children who are
or will get critically ill from AKI are likely to pass through the
emergency department (ED). From the ED perspective, know-
ing the type and/or severity of AKI will help in the judicious
usage of fluid therapy; being more liberal in administering
fluid in fluid responsive (e.g. prerenal azotemia) AKI versus
otherwise (fluid nonresponsive, e.g. acute tubular necrosis).
Early diagnosis will also help avoid usage of potential neph-
rotoxic medication in the ED.
The gold standard kidney function marker, serum creatinine
(SCr), is a poor one for AKI, only rising at a relatively late
stage of kidney injury when intervention is unlikely to be of
benefit. AKI diagnosis is currently based on SCr increase from
baseline or absolute SCr values above a certain threshold
(4–6). Recent data on urinary biomarkers for AKI in the adult
ED have shown that a single novel urinary biomarker, neu-
trophil gelatinase-associated lipocalin (NGAL), was predic-
tive of hospitalization, need for dialysis, and patient mortality,
at a time when SCr was uninformative (7). Shapiro et al. (8)
showed that in patients with suspected sepsis in the ED, an
increased plasma NGAL concentration was associated with
the development of AKI. Thus, there is potential benefit for
the discovery and validation of biomarkers for AKI in the ED
setting (9,10). We have recently shown that urinary NGAL,
independently as well as part of a panel, was able to accurately
predict AKI in the pediatric ED, even in cases where SCr was
normal (11). Ultimately, it is conceivable that a panel of
urinary biomarkers may be needed for better outcomes of
AKI. Thus, there is a significant unmet need to describe
additional early biomarkers that can be diagnostic and prog-
nostic of AKI in the pediatric ED, at a time when baseline SCr
is often unavailable.
NO, a gaseous signaling molecule, is shown to have several
functions in the kidney, depending on its concentration, site of
release, and duration of action (12). Lack of NO generation by
a specific isoform of NO synthase may reflect endothelial
damage in the kidney after ischemia-reperfusion (12,13), the
leading cause of acute tubular necrosis type of AKI. In an
adult postischemic model of AKI, urinary concentration of
NO (as measured by its metabolites nitrate and nitrite) was
markedly lower, suggesting that this was a reflection of po-
tential endothelial damage in the kidney (13). These may be
potential biomarkers for the disease. Thus, we conducted this
study to test the hypothesis that urinary concentration of NO
metabolites, nitrite, and nitrate would be decreased in early
AKI in children presenting to the ED.
METHODS
Study design, study setting, and population. We performed a cross-
sectional single-center evaluation of multiple urinary biomarkers in children
who presented to the Texas Children’s Hospital ED in Houston, TX, from
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January 1 through March 31, 2009. Patients were included if the ED physician
ordered a SCr and urine test as part of the standard of care for evaluation.
Urine was collected in the same manner in all patients using age-appropriate
techniques (catheter or fresh void). Patients were excluded if they had a
known diagnosis of chronic kidney disease including dialysis or transplanta-
tion. Patient caregivers provided informed written consent. The protocol and
consent forms were approved by the Baylor College of Medicine Institutional
Review Board before study commencement (IRB#H-24243).
Study protocol. We assessed the following data at the time of the ED visit:
patient age, gender, height, weight, ethnicity, and vital signs. We also
recorded the primary diagnosis listed on the ED visit written medical record
and categorized these diagnoses by primary organ involvement. If the patient
was admitted to the hospital, we recorded the primary medical or surgical
service of record, length of hospitalization and need for ICU admission,
and/or renal replacement therapy.
Laboratory data. Data from the ED that were required for entry into the
study included SCr and urinalysis. We also recorded any other relevant
laboratory data including complete blood counts, serum and urine electro-
lytes, and liver and pancreatic enzymes. If the patient was admitted, we
recorded subsequent SCr values obtained as part of the patient’s clinical
course; no additional laboratory values were obtained as part of this study.
Urinary biomarker assessment. Urine was obtained for biomarker assess-
ment at the time of urinalysis collection in the ED. Five milliliters of urine
was obtained, spun at 3000 rpm for 15 min, and then the supernatant decanted
into five 1-mL aliquots and stored at 80°C. Combined nitrate and nitrite
(NOx) analysis was performed in the laboratory of one of the authors (N.S.B.)
by a dedicated ENO-20 HPLC System (EiCom Corporation, San Diego, CA)
(14). This system is sensitive and selective for the measurement of NOx in all
biological matrices and has the capacity for high throughput. In brief, to
separate nitrite and nitrate, the nitrate was first reduced to nitrite through a
reaction with cadmium and reduced copper inside a reduction column. The
two resolved peaks were then mixed with Griess reagent (dinitrogen trioxide,
N2O3, generated from acidified nitrite that reacts with sulfanilamide) in-line to
form the classical diazo compound that was then detected spectrophotometri-
cally. Triplicate determinations were performed on each specimen and the
final values averaged.
AKI definition. Patients were classified by the validated pediatric Risk,
Injury, Failure, Loss of function, End-stage renal disease (pRIFLE) criteria
per which AKI outcome can be categorized as Risk, Injury, Failure, Loss of
function, or End-stage renal disease using the changes in estimated creatinine
clearance (eCCl) from baseline eCCl (4,11). Briefly, the pRIFLE criteria
grade AKI severity into pRIFLE-R (Risk; 25–50% change in eCCl),
pRIFLE-I (Injury; 50–75% change), and pRIFLE-F (Failure; 75% change).
Baseline kidney function was defined as the lowest known SCr value in the
previous 3 months. The minimal diagnostic criterion for AKI was a 25%
decrease in eCCl. Patients with no known prior SCr were assumed to have
normal baseline renal function and assigned a baseline eCCl of 120 mL/min/
1.73 m2. This cut-off was chosen because the Schwartz eCCl is known to
overestimate GFR and we have previously validated this cut-off as the most
accurate method when back calculating in patients with known baseline
creatinine values (15).
Data analysis. SPSS version 18 (SPSS Inc., Chicago, IL) was used to
perform the statistical analysis. Patient demographic characteristics were
described using frequencies for categorical variables and measures of central
tendency and dispersion for continuous variables. Distributions were explored
for absolute urinary nitrate and nitrite as well as after normalization to urinary
creatinine; all were found to be non-Gaussian in distribution. Therefore, these
measures were described using medians and compared using nonparametric
methods (Kruskal-Wallis test for multiple groups and Mann-Whitney U test
for two groups). We compared median urinary nitrite and nitrate concentra-
tions across AKI severity categorized by pRIFLE strata: 1) no AKI,
pRIFLE-R, and pRIFLE-I and 2) no AKI and pRIFLE-R combined and
pRIFLE-I. The diagnostic accuracy of normalized urinary nitrate was evalu-
ated using receiver operator characteristic (ROC) techniques.
RESULTS
Demographics and clinical follow-up data. Two hundred
fifty-two patients who met inclusion criteria were enrolled in
the study. Median age was 12 y (range 0–19 y), 50% male,
38% white, 31% Hispanic, 24% black, and 4% Asian. We
observed a high hospitalization rate of 56% (142 patients),
likely because enrollment was restricted to patients who had a
SCr assessed. The median hospital length of stay was 3 d
(range 1–39 d). Only three patients were admitted to the ICU
during hospitalization.
AKI results. The primary diagnostic categories for all the
patients enrolled in the study showed a high prevalence of
diabetic ketoacidosis (32%); gastrointestinal and infectious
disease-related diagnoses were also commonly represented
(14% each). Eighteen of the total 252 patient cohort (7.1%)
had AKI as defined by pRIFLE; 12 (5%) had pRIFLE-R and
6 (2%) had pRIFLE-I. There were miscellaneous primary
diagnoses and organ systems involved in the 18 patients with
AKI: type 1 diabetes mellitus was the commonest (17%).
Fifteen of the admitted patients (11%) had AKI; 10 (7%)
had pRIFLE-R; and 5 (4%) had pRIFLE-I. No patient had or
developed pRIFLE-F. The mean SCr was 0.6  0.26 mg/dL
(range 0.2–2.2 mg/dL) and mean eCCl was 154  40 mL/
min/1.73m2 (range 45–315 mL/min/1.73m2). Sixty patients
(24%) had a baseline SCr within the 3 months before the ED
visit. Demographic data did not differ between patients with
versus without known SCr within the 3 months before the ED
visit.
While the mean SCr was higher and corresponding mean
eCCl lower, for patients with AKI, nine of the AKI patients
had SCr 1 mg/dL and six had eCCl 90 mL/min/1.73m2 in
the ED. Thus, 33–50% of the patients with AKI calculated by
pRIFLE may not have had AKI identified by the SCr value
alone at the time of ED visit.
The rate of AKI detection by pRIFLE was higher in patients
with versus patients without a known baseline SCr (8.7 versus
4.9%, p  0.03). Fifty-four (38%) of the hospitalized patients
had a subsequent SCr measured as part of the course of their
clinical care, none of whom developed new onset or worsen-
ing AKI.
Urinary nitrite and nitrate results. We compared urinary
biomarker concentrations for the entire 252 patient cohort
across AKI severity by pRIFLE strata. Figure 1 shows abso-
lute median urinary nitrate values in the three groups; there
Figure 1. Absolute median urinary nitrate concentrations in patients present-
ing to TCH-ED with no AKI, at risk for AKI (pRIFLE-R), and those with
injury (pRIFLE-I; n  252 patients). Data are shown as box plots with the
heavy line in the box representing the median (50th percentile) and the ends
of the box representing 25th and 75th percentiles, respectively. Groups were
compared using the nonparametric Kruskal-Wallis test *(p 0.03). TCH, TX
Children’s Hospital.
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was a significant decline in urinary nitrate in pRIFLE-I versus
pRIFLE-R or the no AKI groups (p  0.033 by Kruskal-
Wallis test). Table 1 lists the results for the controls (no AKI)
and AKI patients (pRIFLE-R and pRIFLE-I) as absolute
values of nitrite and nitrate (M) and normalized to urinary
creatinine (g/mg Cr). Using the Kruskal-Wallis test, urinary
nitrate normalized to creatinine was significantly lower in
pRIFLE-I versus pRIFLE-R or the no AKI groups (p 
0.036). A separate analysis of urinary biomarker levels re-
vealed absolute median urinary nitrate to be significantly
lower for the injury group (pRIFLE-I) compared with the
combined risk (pRIFLE-R) and no AKI groups (p  0.012;
Table 2). Urinary nitrate normalized to creatinine was also
significantly lower (712 g/mg Cr in the combined group
versus 389 g/mg Cr in pRIFLE-I; p 0.020). Urinary nitrite
failed to show any significant differences between the AKI
versus no AKI groups.
Urinary biomarker diagnostic characteristics. Figure 2
shows the ROC curve to predict the sensitivity and specificity
of urinary nitrate for AKI and to predict the presence of
pRIFLE-I. Diagnostic accuracy using ROC curve analysis of
urinary nitrate demonstrated good accuracy, area under curve
[(AUC) 0.778; 95% CI 0.642–0.914] to predict patients with
pRIFLE-I versus patients with pRIFLE-R or without AKI.
Maximizing both sensitivity and specificity, the best cut point
for the identification of pRIFLE-I was a normalized nitrate
410 g/mg Cr with sensitivity 66.6% and specificity 80.9%.
DISCUSSION
Data from our study provide the first evidence that urinary
nitrate, a metabolite of NO, is associated with early AKI in the
pediatric ED setting. This is at a time when baseline kidney
function, as reflected by SCr, is normal, unchanged, or most
often, unavailable. An important aspect of our study was that
the majority of patients (75%) did not have a SCr available in
the 3 months before the ED visit. This highlights the potential
utility of a urinary biomarker to detect acute illness in the setting
of unknown baseline kidney function. Nitrate is the predominant
urinary NO-based metabolite, whereas nitrite is low to undetect-
able in urine (16). Hence, it is not surprising why nitrate and not
nitrite was the more informative of the two.
Our findings are supported by the study by Kwon et al. (13)
which showed diminished excretion of urinary NO metabo-
lites in postischemic AKI, albeit the study was done in adult
recipients of cadaveric renal allografts. Ischemia is the most
common cause of AKI in both native and transplanted kid-
neys, with cardiac arrest, sepsis, and shock exposing the
kidney to ischemic injury (13). Recent findings have sug-
gested that endothelial injury acts as a primary event leading
to renal hypoxia with disturbances in NO pathways playing a
major role (12). Studies have suggested that these metabolites
Figure 2. ROC curve for normalized urinary nitrate (g/mg Cr) to predict the
presence of pRIFLE-I.
Table 1. Urinary nitrite and nitrate concentrations in patients by pRIFLE strata
Total
pRIFLE category
No AKI Risk Injury p*
N 252 234 12 6
Median nitrite (IQR)† (M) 0.06 (0.00, 0.15) 0.06 (0.00, 0.14) 0.07 (0.00, 0.32) 0.10 (0.06, 0.84) 0.463
Median nitrite/Cr‡ (IQR) (g/mg Cr) 0.06 (0, 0.23) 0.06 (0, 0.2) 0.05 (0, 0.24) 0.24 (0.03, 2.34) 0.331
Median nitrate (IQR) (M) 512.26 (255, 1122) 550.1 (261, 1140) 394.5 (214, 1017) 192.3 (125, 339) 0.033
Median nitrate/Cr (IQR) (g/mg Cr) 707.98 (443, 1200) 717.9 (450, 1229) 634.6 (317, 852) 389.2 (249, 591) 0.036
* Using Kruskal-Wallis test for nonparametric measures.
† Interquartile range (IQR) for medians.
‡ All values/Cr normalized per mg of Cr.
Table 2. Urinary nitrite and nitrate concentrations in patients by combined pRIFLE strata
Total
pRIFLE category
No AKI and pRIFLE-R pRIFLE-I p*
N 252 246 6
Median nitrite (IQR)† (M) 0.06 (0.00, 0.15) 0.06 (0.00, 0.15) 0.10 (0.06, 0.84) 0.219
Median nitrite/Cr‡ (IQR) (g/mg Cr) 0.06 (0, 0.23) 0.061 (0, 0.22) 0.244 (0.03, 2.34) 0.142
Median nitrate (IQR) (M) 512.26 (255.75, 1122.22) 548.57 (260.85, 1134.22) 192.25 (125.50, 339.67) 0.012
Median nitrate/Cr (IQR) (g/mg Cr) 707.98 (443.41, 1200.41) 712.38 (449.61, 1220.14) 389.19 (249.33, 591.22) 0.020
* Using Mann-Whitney U test for nonparametric measures.
† Interquartile range (IQR) for medians.
‡ All values/Cr normalized per mg of Cr.
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may be useful markers of endogenous NO synthase activity
(17). Thus, diminished urinary nitrate in patients with early
AKI may reflect diminished endothelial production of NO and
suggests targeting the NO pathway as a means to treat or
prevent the development of AKI.
The morbidity we observed was far less severe; no patients
required dialysis; only three patients required ICU admission
and we did not observe any patient mortality. However, given
that urinary nitrate was lower in patients with pRIFLE-I, we
speculate that this biomarker may detect AKI presence and
severity in more severely ill children, similar to what was
observed for a different set of urinary biomarkers, including
NGAL, in a previous study of critically ill children (18,19).
However, larger numbers of patients need to be enrolled in
more prospective studies to confirm that urinary nitrate can
predict severe outcome in children.
We attempted to distinguish sepsis or ischemic causes from
the rest, but lack of clear-cut diagnostic categories such as the
above and the small number of cases for pRIFLE-I (n  6)
precluded adequate statistical comparison. As hydration status
was readily available, we compared urinary biomarkers be-
tween patients with and without dehydration; no significant
difference was obtained for the biomarkers NGAL and nitrate
(data not shown). Nitrate being a relatively novel urinary
biomarker prompted us to internally validate it for AKI. Using
the cutoff points from the ROC curves for the values that
corresponded to the highest diagnostic accuracy, the correla-
tion between the urinary nitrate and NGAL was 0.32. Specif-
ically, of the six patients with renal injury, five would be
correctly identified by NGAL and four by nitrate. Three would
overlap and all identify the injury.
Our study had limitations. We only had a single measure-
ment of urinary NO metabolites during the ED admission and
are thus unable to conclusively correlate changes in markers
with subsequent changes in renal function in hospitalized
patients. The number of patients with AKI in the ED was
relatively small compared with adult studies. However, our
study represents the largest single group of children with AKI
in the ED from whom urinary NO metabolites have been
assessed. We also did not observe any patients with pRIFLE-F
(Failure). Because 96% of the filtered nitrite and nitrate is
reabsorbed in the renal tubules (20), we speculate that
pRIFLE-F may be associated with an increase in urinary NO
metabolites due to reduced reabsorption. Enrolling sicker
patients will also enable us to assess if urinary NO metabolites
are associated with important patient outcome parameters
such as the need for ICU admission, renal replacement ther-
apy, hospital length of stay, or patient mortality.
Plasma and urinary levels of nitrate are extremely variable
in the individual and between individuals, mainly due to the
impact of dietary NOx and endogenous formation of NO (16).
Thus, human plasma and urinary nitrate measurements are
recommended only after a low NOx diet for at least 4 d (16).
However, given the rapid clinical setting of the ED, ensuring
a low dietary NOx state in the patient before collection of
specimens would be exceedingly hard. Furthermore, our re-
sults indicated an effect on urinary nitrate that was opposite to
what one would predict given high levels of dietary nitrate,
and thus this may be a valid tool in the ED setting. We did not
confirm return of the low urinary nitrate excretion to normal
after recovery in patients with pRIFLE-I because our study
was not designed to collect follow-up urinary specimens.
Future prospective study would be needed to elucidate this
important aspect because NO production is low in chronic
kidney disease and the low urinary nitrate excretion could
reflect chronic rather than acute kidney disease.
We are aware of overlap between the groups and the
difficulty that arises with a biomarker that is potentially diag-
nostic when the concentration is low. Our study was not
powered to determine the diagnostic accuracy of urinary
nitrate, and that coupled with the small number of patients
with pRIFLE-I likely explains the high steps on the ROC
curve in Figure 2. Our study was not designed to collect and
bank extra blood specimens for plasma AKI biomarkers, and
thus we could not attempt correlations between plasma NOx
and urinary NOx. Plasma NOx would have enabled us to
determine the fractional excretion of urinary NO metabolites,
potentially a more informative parameter. Ongoing studies
will address all the above issues.
In conclusion, our study indicates that in the pediatric ED,
decreased urinary nitrate, as a proxy for NO, may be an early
biomarker for acute AKI. Given the low prevalence of AKI in
our patient group in the ED, it is not prudent to speculate that
in all the AKI detected there was an ischemic component
given the association with low urinary nitrate. Prospective
cohort studies with larger numbers and of more severely ill
AKI patients will be required to truly ascertain if urinary nitrate
levels obtained in the ED setting can serve well to predict
important in-patient clinical outcomes. These studies will enable
us to (1) control for potential confounders such as dietary NOx
and (2) obtain plasma NOx to determine correlations with urinary
NOx in pediatric AKI. Finally, additional work is required to
determine whether diminished urinary nitrate in AKI is truly
indicative of renal endothelial dysfunction.
REFERENCES
1. Lameire N, Van Biesen W, Vanholder R 2005 Acute renal failure. Lancet 365:417–
430
2. Devarajan P 2006 Update on mechanisms of ischemic acute kidney injury. J Am Soc
Nephrol 17:1503–1520
3. Devarajan P 2007 Emerging biomarkers of acute kidney injury. Contrib Nephrol
156:203–212
4. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein
SL 2007 Modified RIFLE criteria in critically ill children with acute kidney injury.
Kidney Int 71:1028–1035
5. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P 2004 Acute renal failure-
definition, outcome measures, animal models, fluid therapy and information tech-
nology needs: the Second International Consensus Conference of the Acute Dialysis
Quality Initiative (ADQI) Group. Crit Care 8:R204–R212
6. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A;
Acute Kidney Injury Network 2007 Acute Kidney Injury Network: report of an
initiative to improve outcomes in acute kidney injury. Crit Care 11:R31
7. Nickolas TL, O’Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C,
Khan F, Mori K, Giglio J, Devarajan P, Barasch J 2008 Sensitivity and specificity of
a single emergency department measurement of urinary neutrophil gelatinase-
associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 148:810–
819
8. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, Moretti E,
Nguyen HB, Gunnerson K, Milzman D, Gaieski DF, Goyal M, Cairns CB, Kupfer
K, Lee SW, Rivers EP 2010 The diagnostic accuracy of plasma neutrophil gelati-
nase-associated lipocalin in the prediction of acute kidney injury in emergency
department patients with suspected sepsis. Ann Emerg Med 56:52–59.e1
9. Di Grande A, Giuffrida C, Carpinteri G, Narbone G, Pirrone G, Di Mauro A,
Calandra S, Noto P, Le Moli C, Alongi B, Nigro F 2009 Neutrophil gelatinase-
206 MIAN ET AL.
associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury
in the emergency department. Eur Rev Med Pharmacol Sci 13:197–200
10. Self WH, Barrett TW 2010 Novel biomarkers: help or hindrance to patient care in
the emergency department? Ann Emerg Med 56:60–61
11. Du Y, Zappitelli M, Mian A, Bennett M, Ma Q, Devarajan P, Mehta R, Goldstein SL
2011 Urinary biomarkers to detect acute kidney injury in the pediatric emergency
center. Pediatr Nephrol 26:267–274
12. Goligorsky MS, Brodsky SV, Noiri E 2002 Nitric oxide in acute renal failure: NOS
versus NOS. Kidney Int 61:855–861
13. Kwon O, Hong SM, Ramesh G 2009 Diminished NO generation by injured
endothelium and loss of macula densa nNOS may contribute to sustained acute
kidney injury after ischemia-reperfusion. Am J Physiol Renal Physiol 296:F25–F33
14. Bryan NS, Grisham MB 2007 Methods to detect nitric oxide and its metabolites in
biological samples. Free Radic Biol Med 43:645–657
15. Zappitelli M, Parikh CR, Akcan-Arikan A, Washburn KK, Moffett BS, Goldstein SL
2008 Ascertainment and epidemiology of acute kidney injury varies with definition
interpretation. Clin J Am Soc Nephrol 3:948–954
16. Kelm M 1999 Nitric oxide metabolism and breakdown. Biochim Biophys Acta
1411:273–289
17. Elli M, Soylemezoglu O, Erbas D, Bakkaloglu SA, Buyan N, Ozkaya O, Hasanoglu
E 2005 Plasma and urine nitric oxide levels in healthy Turkish children. Pediatr
Nephrol 20:1605–1609
18. Zappitelli M, Washburn KK, Arikan AA, Loftis L, Ma Q, Devarajan P, Parikh CR,
Goldstein SL 2007 Urine neutrophil gelatinase-associated lipocalin is an early
marker of acute kidney injury in critically ill children: a prospective cohort study.
Crit Care 11:R84
19. Washburn KK, Zappitelli M, Arikan AA, Loftis L, Yalavarthy R, Parikh CR,
Edelstein CL, Goldstein SL 2008 Urinary interleukin-18 is an acute kidney
injury biomarker in critically ill children. Nephrol Dial Transplant 23:566-
572
20. Rahma M, Kimura S, Yoneyama H, Kosaka H, Nishiyama A, Fukui T, Abe Y 2001
Effects of furosemide on the tubular reabsorption of nitrates in anesthetized dogs.
Eur J Pharmacol 428:113–119
207URINARY NITRATE AND ACUTE KIDNEY INJURY
